Benchmark today announced its Q1 Results for the three months ended 31 December 2023. Some key highlights include the launch of a new Salmon ova product line, continual Innovation with the successful commercialisation of our new AI tool SnappArt and CleanTreat® and Ectosan®Vet progressing on a wellboat configuration.
We have had a busy quarter where we have maintained momentum in our two largest business areas and the Group is on track to meet management’s expectations for the year. We have good visibility of revenues in Genetics, continuing good performance in Advanced Nutrition and have taken actions in Health to transition to a new business model for Ectosan® Vet and CleanTreat® which will increase its commercial attractiveness and strengthen our portfolio of sea lice solutions.
We have a busy year ahead and intend to stay focused to deliver continued progress towards our goals. Longer term, as a supplier of specialised mission critical solutions to aquaculture producers worldwide, Benchmark is uniquely positioned in an industry with significant structural growth trends with significant opportunities ahead.
Trond Williksen CEO
